2022 Jul 6;15(1):9503. doi: 10.4081/dr.2022.9503. All patients are currently in good general health. Before Pityriasis rosea (PR)-like eruption is a cutaneous complication associated with several medications and vaccinations. Suchonwanit P, Rojhirunsakool S, Khunkhet S. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. 2021;35(9):e546e548. Due to the temporal relationship between vaccination and onset of rash, COVID-19 vaccination was the most likely etiology. Here, we described a case of PR-like eruption that developed 14 days after Oxford/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. Background: If you develop pityriasis rosea, you may experience the following in this order: Feel ill for 1 or 2 days Develop a large patch on your skin Get many smaller patches or bumps on your skin See your skin clear SV, supervised the work. Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature. tions reported after vaccination include: injection site reactions, urticarial and morbilliform eruptions, per-nio/chilblains, reactions to cosmetic llers, herpes zoster, herpes simplex ares, and pityriasis rosea-like rashes [1]. The .gov means its official. "Urticarial lesions" were identified in 19 per cent of COVID-19 patients, likened to a nettle rash with pink or white raised areas of the skin. Vaccine-Related Eruptions of Papules and Plaques Following COVID-19 Vaccination - A Case Series. Cite this: Skin Reactions After COVID-19 Vaccination . With COVID-19 vaccines being authorized for emergency use, monitoring for potential adverse effects (e.g., cutaneous reactions) is necessary. Atzori L, Pinna AL, Ferreli C, Aste N. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. But there are important differences between these 2 conditions. While COVID-19 vaccines offer strong and lasting protection against severe . and the adverse cutaneous effects of COVID-19 . Bookshelf However, adverse effects to COVID-19 vaccines, particularly cutaneous reactions, have been reported. Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Epub 2022 Jun 13. Polack FP, Thomas SJ, Kitchin N, et al. Unable to load your collection due to an error, Unable to load your delegates due to an error. Future studies should investigate oral lesions in SARS-CoV-2-positive subjects and after COVID-19 vaccination in the pediatric population, taking into account viral variants and newly developed vaccines. Human herpesviruses 6 and 7 are common. doi: 10.1111/bjd.20143. official website and that any information you provide is encrypted Dermatol Ther. FOIA -, Johansen M, Chisolm SS, Aspey LD, Brahmbhatt M. Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: a report of 2 cases. government site. Epub 2021 Apr 7. (2021) p. e15040. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. Following the national COVID-19 vaccination guidelines, she received a shot of ChAdOx1 nCoV-19 (AZD1222) vaccine before the therapy. Pityriasis is linked mainly with herpesviruses 6 and 7; only a . The duration of the infection ranges from two weeks to three months. PRISMA, preferred reporting items for systematic reviews and metaanalysis. Bookshelf 7 Articles, This article is part of the Research Topic, Creative Commons Attribution License (CC BY), Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Before Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them? Cazzato G, Ambrogio F, Foti C, Capuzzolo M, Trilli I, Casatta N, Lupo C, Carrieri M, Daini D, Colagrande A, Maiorano E, Ingravallo G. Diagnostics (Basel). Pityriasis rosea is a rash that often begins as an oval spot on the face, chest, abdomen or back. Keywords: FOIA Pityriasis rosea is a common skin disease that is not contagious. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. government site. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. 1 Several vaccines have been developed to fight against COVID19, to prevent the transmission among susceptible individuals and to decrease the morbidity Few brownish patches also appeared, suggestive of post-inflammatory hyperpigmentation. Unauthorized use of these marks is strictly prohibited. Lasers Med Sci. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review. It is increasingly recognized that SARS-CoV-2 infection and COVID-19 vaccines have been associated with skin disorders, including pityriasis rosea. (2017) 9:7399. doi: 10.4081/dr.2017.7399, 17. Careers. tivation is associated with pityriasis rosea-like eruption.6 Our cases of herpes simplex and pityriasis rosea-like eruption occurred in male patients following the first dose of BioNTech, whereas one female patient suffered herpes zoster following the third dose of CoronaVac. Among patients who received COVID-19 vaccines, PR-like eruptions have been reported following the first (n = 1) or second dose (n = 2) of BNT162b2 mRNA-based vaccines (3, 4). Results: Spongiotic dermatitis was the most commonly reported cutaneous reaction to COVID-19 vaccination among patients who also had biopsy results available for review, according to a registry-based. eCollection 2022. Accessed February 2, 2022. Epub 2022 Feb 9. In 3 patients a biopsy for histopathological examinations was carried out. Pityriasis rosea (PR) is an acute papulosquamous cutaneous disorder that classically presents with a herald patch rapidly followed by a widespread rash along skin cleavage lines. Most people with the rash are 10 to 35 years of age. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review. Drago F, Ciccarese G, Rebora A, et al. Pregnant women are in a high-risk group for serious complications from pityriasis rosea. sharing sensitive information, make sure youre on a federal Explore the world of Jaguar cars and learn more about models HHS Vulnerability Disclosure, Help (2021) 35:e5468. Polack FP, Thomas SJ, Kitchin N et al. 2021;185(2):e34. Suchonwanit P, Triamchaisri S, Wittayakornrerk S, Rattanakaemakorn P. Leprosy Reaction in Thai Population: A 20-Year Retrospective Study. -, Rasheed R, Rizwan A, Javed H, Sharif F, Zaidi A. Socioeconomic and environmental impacts of COVID19 pandemic in Pakistanan integrated analysis. This site needs JavaScript to work properly. 15 Pityriasis rosea and COVID19 S. Veraldi, C. Spigariolo Medicine Journal of medical virology 2020 As with eczema, the conditions can be differentiated under the microscope by their acanthotic or non-acanthotic appearance. An official website of the United States government. Unable to load your collection due to an error, Unable to load your delegates due to an error. Postgrad Med J. National Library of Medicine Veraldi S, Boneschi V, Cusini M, Maronese CA. eCollection 2022 Jul. McMahon DE, Amerson E, Rosenbach M, et al.. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. Dermatol Online J. -. Table 1 summarizes all reported cases of PR-like eruption following COVID-19 vaccination. 2022 Sep-Oct;40(5):586-590. doi: 10.1016/j.clindermatol.2022.01.002. 2022 Jul 6;15(1):9503. doi: 10.4081/dr.2022.9503. 2022 Feb 3;9 (2):003164. doi: 10.12890/2022_003164. 2022 Aug;35(8):e15602. Data were independently extracted and accessed for bias. Please enable it to take advantage of the complete set of features! 2021;23(3):221228. Pityriasis rosea developing after COVID19 vaccination. Epub 2022 Jul 19. However, the etiopathogenetic mechanisms remain largely unknown and further studies are needed in order to clarify the correlation between SARS-CoV-2 and PR. 2022 Sep-Oct;40(5):586-590. doi: 10.1016/j.clindermatol.2022.01.002. The latter is found in a younger age group. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations. Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination. J Eur Acad Dermatol Venereol. Limitations: Registry analysis does not measure incidence. An official website of the United States government. Moreover, central dusky-red erythematous was observed on some plaques (Figure 2A). 2021 Sep;60(9):1150-1151.doi: 10.1111/ijd.15700. eCollection 2021. PS conceptualized the case report and revised the manuscript. Efficacy and safety of COVID19 vaccines: a systematic review. These types cannot cause cold sores or genital herpes. As previously mentioned, only some cases of PR/PRLE after anti-SARS-CoV-2 vaccination have been reported (Table 2).1-18, PRLE usually appears following a drug, without prodromal symptoms. Moreover, almost all lesions faded with associated post-inflammatory hyperpigmentation (Figure 2B). Would you like email updates of new search results? Secukinumab for pityriasis rubra pilaris (December 2022) SKIN CANCER. These findings were consistent with a diagnosis of PR-like eruption. Bethesda, MD 20894, Web Policies (2020) 33:e13878. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Within two weeks of topical betamethasone dipropionate treatment, the lesions disappeared completely. Peripheral eosinophilia is often present. Variable dermatological manifestations including acral erythema, urticaria, vasculitis, vesicular or pustular eruptions, maculopapular rash have all been reported during the course of COVID19. Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: Lessons learned from current evidence. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. See this image and copyright information in PMC. doi: 10.1111/jdv.17301. Only a few cases of pityriasis rosea (PR)/pityriasis rosea-like eruption (PRLE) after anti-SARS-CoV-2 vaccination have been reported. CONCLUSION: The association between pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease. Epub 2021 Jun 10. Busto-Leis JM, Servera-Negre G, Mayor-Ibarguren A, Sendagorta-Cuds E, Feito-Rodrguez M, Nuo-Gonzlez A, et al. An official website of the United States government. 2021;85(1):4655. SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. doi: 10.1016/j.jaad.2021.03.092, 15. The average age of incidence was calculated to be 44.92 years, and 63 (62.37%) people presented after administration of the first dose.